Additional file 1: of Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Soda, Hitoshi; Maeda, Hiromichi; Hasegawa, Junichi; Takahashi, Takao; Hazama, Shoichi; Fukunaga, Mutsumi; Kono, Emiko; Kotaka, Masahito; Sakamoto, Junichi; Nagata, Naoki; Oba, Koji; Mishima, Hideyuki

doi:10.6084/m9.figshare.c.3635300_D2.v1

12885_2015_1685_MOESM1_ESM.docx (17.19 kB)

Additional file 1: of Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

journal contribution

posted on 2015-10-14, 05:00 authored by Hitoshi Soda, Hiromichi Maeda, Junichi Hasegawa, Takao Takahashi, Shoichi Hazama, Mutsumi Fukunaga, Emiko Kono, Masahito Kotaka, Junichi Sakamoto, Naoki Nagata, Koji Oba, Hideyuki Mishima

Table listing the Central ethics committee and the IRBs of the participating institutes. The IRB of each participating institute reviewed and approved the protocol of the present study. (DOCX 17Â kb)